HBeAg levels at week 24 predict response to 8years of tenofovir in HBeAg-positive chronic hepatitis B patients

Wong, D; Littlejohn, M; Yuen, L; Jackson, K; Mason, H; Bayliss, J; Rosenberg, G; Gaggar, A; Kitrinos, K; Subramanian, M; Marcellin, P; Buti, M; Janssen, HLA; Gane, E; Locarnini, S; Thompson, A; Revill, PA

Revill, PA (reprint author), Royal Melbourne Hosp, Peter Doherty Inst Infect & Immun, Victorian Infect Dis Reference Lab, Div Res & Mol Dev, Parkville, Vic 3000, Australia.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018; 47 (1): 114

Abstract

BackgroundHepatitis B e antigen (HBeAg) seroconversion is a treatment endpoint for HBeAg-positive CHB, and a necessary precursor to HBsAg loss. Biomar......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索